Quick Links
Phillip Frost has an estimated net worth of $1.7 billion. Phillip Frost's successful career started when he worked as a Lieutenant commander at the National Cancer Institute of the US Public Health Service. He then worked as a professor of dermatology at the University of Miami and he became the head of the Dermatology Department at the Mt. Sinai Medical Center of Greater Miami Florida.
In 1972, together with Michael Jaharis, Phillip Frost bought the Key Pharmaceuticals Inc. The company was later acquired by Schering-Plough for $600 million. Frost received $100 for the sale. In 1987, Frost served as the Chief Executive Officer and Chairman of the Board of Directors at IVAX Corporation. In 2006, the company was acquired by an Israel-based pharmaceutical company Teva for $7.4 billion. He then served as the Vice-Chairman of Teva in January 2006. In 2010, he became the Chairman of the Board of Directors and in May 2012, he was re-elected to the post.
Frost invested $24 million in Protalix BioTherapeutics making him the largest investor to the said company which developed the treatment for Gaucher Disease.
Earnings & Financial Data
|
Date |
Category |
Description |
Amount |
|---|---|---|---|
|
2019 |
Asset |
Purchase value of Philip Frost's 1.63 million shares in OPKO Health Inc. |
$3,200,000 |
|
2019 |
Earning Turned Donation |
Donation of Philip and Patricia Frost to the University of Miami |
$100,000,000 |
|
2019 |
Asset |
Estimated value of Philip Frost's equities in various companies which includes Opko Health Inc. (OPK) Pharmaceuticals, Vector Group Ltd (VGR) Tobacco, Fluent Inc (FLNT) Business Support Services, Castle Brands Inc (ROX) Distillers & Wineries, LADG THALP (LTS.PRA), Red Violet Inc (RDVT) Software, Ladenburg Thalmann Financial Services (LTS) Investment Banking & Brokerage Services, BioCardia Inc (BCDA) Medical Equipment, Supplies & Distribution, Cocrystal Pharma Inc (COCP) Pharmaceuticals, Non-Invasive Monitoring Systems, Inc., and Chromadex Corp (CDXC) Biotechnology & Medical Research |
$1,040,000,000 |
|
2018 |
Earnings |
Sales or revenue of OPKO Health Inc. as the company's Chairman & Chief Executive Officer |
$990,270,000 |
|
2018 |
Earnings |
Total compensation as the Chief Executive Officer of Opko Health Inc. |
$2,040,000 |
|
2018 |
Asset |
Total equities as the Chief Executive Officer of Opko Health Inc. |
$1,070,000 |
|
2018 |
Salary |
Base salary as the Chief Executive Officer of Opko Health Inc. |
$960,000 |
|
2018 |
Sale of Asset |
Sale of Philip Frost's shares in OPKO to Ladenburg |
$130,250,000 |
|
2018 |
Earnings |
Money generated from Philip Frost's "pump-and-dump" scheme of unlawful stock sales |
$27,000,000 |
|
2018 |
Asset |
Purchase value of Philip Frost's 105,263 shares in OPKO Health, Inc. |
$200,000 |
|
2017 |
Asset |
Money raised from the Series C of Eloxx |
$38,000,000 |
|
2017 |
Earning Turned Donation |
Donation to the University of Miami to support basic and applied sciences and engineering for the construction of a modern science and engineering building on the University's Coral Gables campus, to be named the Phillip and Patricia Frost Science and Engineering Building, creation of at least 13 chairs in STEM fields and graduate student support |
$100,000,000 |
|
2017 |
Earning Turned Donation |
Donation for the construction of Miami's new 250,000-square-foot Patricia & Phillip Frost Museum of Science which has a planetarium and a massive multilevel marine aquarium |
$45,000,000 |
|
2015 |
Earning Turned Donation |
Donation to support the new Miami Museum Park’s state-of-the-art planetarium |
$10,000,000 |
|
2015 |
Asset |
Money raised from the Post-IPO Equity of MabVax Therapeutics |
$11,600,000 |
|
2014 |
Asset |
Estimated value of Philip Frost's 386,928 shares in MusclePharm MSLP |
$3,000,000 |
|
2014 |
Asset |
Philip Frost's investment in Drone Aviation Holding Corp. which allowed him to become a part of their strategic advisory board |
$825,000 |
|
2013 |
Asset |
Philip Frost's initial investment in the American nutritional supplement company MusclePharm MSLP |
$1,400,000 |
|
2013 |
Asset |
Estimated value of Philip Frost's 5,000-square-foot estate in South Florida |
$58,000,000 |
|
2011 |
Earning Turned Donation |
Philip Frost's donation towards the construction of the new Miami Science Museum building at Bicentennial Park in Downtown Miami that was eventually named the Phillip and Patricia Frost Museum of Science |
$35,000,000 |
|
2010 |
Asset |
Money raised from the Venture Round of 5to1 and Fabrus |
$8,500,000 |
|
2010 |
Asset |
Purchase value of Philip Frost's 10,000 units of OPK stock |
$20,200 |
|
2007 |
Earning Turned Donation |
Philip Frost's donation of Protalix shares to a charitable organization |
$8,000,000 |
|
2007 |
Asset |
Philip Frost's investment in Protalix BioTherapeutics, that eventually developed a U.S. Food and Drug Administration-approved treatment for Gaucher disease |
$24,000,000 |
|
2005 |
Sale of Asset |
Sale of Philip Frost's generic drugmaker Ivax to Teva Pharmaceuticals |
$7,600,000,000 |
|
2003 |
Earning Turned Donation |
Philip Frost's gift to the University of Miami's School of Music making the school officially renamed as the Phillip and Patricia Frost School of Music |
$33,000,000 |
|
1986 |
Sale of Asset |
Sale of Philip Frost and and Michael Jaharis' company Key Pharmaceuticals after the reformulation its asthma drug |
$836,000,000 |